New Blood Test Aims for Early Cancer Detection
A groundbreaking blood test might be a significant step forward in the early detection of multiple cancers. This test, known as Galleri, was studied by a research group in California and claims to identify over 50 different types of cancer.
In the study, around 23,161 people from the U.S. and Canada, all over the age of 50 and symptom-free, were included. Participants received standard screening tests recommended for certain cancers like breast, cervical, colorectal, and lung cancer, alongside the Galleri blood test developed by the biotechnology company Grail.
The focus was on comparing the outcomes of standard screenings alone to those that included the Galleri test.
Out of those who were tested, the Galleri method indicated cancer in 216 individuals. Further investigation confirmed that 133 of these people indeed had cancer. This led to a detection accuracy of about 61.6%, meaning that a positive Galleri result suggests a strong chance of having the disease. The study also noted a remarkably low false positive rate of about 0.4%.
Impressively, more than half, specifically 53.5%, of the cancers caught by Galleri were at stages 1 or 2, with about 69.3% being early-stage. This suggests that a large portion of these detected cancers currently have no standard screening methods in the U.S.
The research showed a sevenfold increase in cancer detection when the Galleri blood test was used alongside traditional screening methods. Dr. Nima Nababizadeh, one of the study’s authors, expressed enthusiasm about these findings, highlighting the potential for addressing unmet needs in cancer screening and the importance of early detection.
Josh Offman, the president of GRAIL, emphasized that many of the deadliest cancers are diagnosed at late stages. He pointed out that integrating Galleri into routine screenings could enable earlier intervention for various cancers.
Not a Replacement, But a Complement
Dr. Nicole Saphier, a medical contributor who was not part of the study, shared her thoughts on the promising results, emphasizing the potential for early detection to significantly impact treatment affordability and outcomes. She remarked on how vital it is to catch cancers when they’re most treatable, allowing individuals to lead healthier lives.
While the Galleri test adds value to existing screening methods for breast, cervical, colorectal, and lung cancers, experts caution against viewing it as a replacement. It should serve as an addition to the current screening options.
In light of rising cancer rates among younger populations, there’s ongoing discussion about whether screening age thresholds should be adjusted and how the Galleri test might influence this decision.
However, the study’s design had limitations, as it did not involve a control group for a direct comparison of outcomes. Future expansions in data analysis are expected, including a broader investigation with all participants involved.
Ongoing trials, like the NHS-Galleri randomized test, are anticipated to provide additional insights and help clarify the clinical utility of the Galleri test in comparison to standard care methods, underscoring the importance of thoughtful integration of new technologies into established practices.
